Table 8 NBI predicted drug-disease associations (top 10 in ranking list), and the corresponding evidence
From: Drug repositioning based on individual bi-random walks on a heterogeneous network
Drug | Disease | Evidence (PMID) | Rank |
|---|---|---|---|
Flurandrenolide | Facial Dermatoses | without evidence | 1 |
Levofloxacin | Urinary Tract Infections | 25931244 | 2 |
Cefoperazone | Escherichia coli Infections | without evidence | 3 |
Flurandrenolide | Scalp Dermatoses | without evidence | 4 |
Ceftazidime | Proteus Infections | without evidence | 5 |
Ceftizoxime | Escherichia coli Infections | 24755996 | 6 |
Moxifloxacin | Streptococcal Infections | 19188393;18818055;17562794 | 7 |
Cefpodoxime | Escherichia coli Infections | 23537823 | 8 |
Ofloxacin | Streptococcal Infections | 19856068 | 9 |
Ampicillin | Streptococcal Infections | 2306432 | 10 |